Literature DB >> 30958470

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models.

Seth A Bennett1, Samantha N Cobos2, Marcella Meykler3, Michel Fallah3, Navin Rana3, Karen Chen3, Mariana P Torrente4.   

Abstract

Neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), cause the loss of hundreds of thousands of lives each year. Effective treatment options able to halt disease progression are lacking. Despite the extensive sequencing efforts in large patient populations, the majority of ALS and PD cases remain unexplained by genetic mutations alone. Epigenetics mechanisms, such as the post-translational modification of histone proteins, may be involved in neurodegenerative disease etiology and progression and lead to new targets for pharmaceutical intervention. Mammalian in vivo and in vitro models of ALS and PD are costly and often require prolonged and laborious experimental protocols. Here, we outline a practical, fast, and cost-effective approach to determining genome-wide alterations in histone modification levels using Saccharomyces cerevisiae as a model system. This protocol allows for comprehensive investigations into epigenetic changes connected to neurodegenerative proteinopathies that corroborate previous findings in different model systems while significantly expanding our knowledge of the neurodegenerative disease epigenome.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30958470      PMCID: PMC6543847          DOI: 10.3791/59104

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  37 in total

Review 1.  Characterization of histones and their post-translational modifications by mass spectrometry.

Authors:  Benjamin A Garcia; Jeffrey Shabanowitz; Donald F Hunt
Journal:  Curr Opin Chem Biol       Date:  2006-12-06       Impact factor: 8.822

Review 2.  Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era.

Authors:  Ximena Paez-Colasante; Claudia Figueroa-Romero; Stacey A Sakowski; Stephen A Goutman; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

3.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

Review 4.  Parkinson disease.

Authors:  Werner Poewe; Klaus Seppi; Caroline M Tanner; Glenda M Halliday; Patrik Brundin; Jens Volkmann; Anette-Eleonore Schrag; Anthony E Lang
Journal:  Nat Rev Dis Primers       Date:  2017-03-23       Impact factor: 52.329

5.  Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1.

Authors:  Michael Tibshirani; Miranda L Tradewell; Katie R Mattina; Sandra Minotti; Wencheng Yang; Hongru Zhou; Michael J Strong; Lawrence J Hayward; Heather D Durham
Journal:  Hum Mol Genet       Date:  2014-09-30       Impact factor: 6.150

6.  FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.

Authors:  Manuela Neumann; Eva Bentmann; Dorothee Dormann; Ali Jawaid; Mariely DeJesus-Hernandez; Olaf Ansorge; Sigrun Roeber; Hans A Kretzschmar; David G Munoz; Hirofumi Kusaka; Osamu Yokota; Lee-Cyn Ang; Juan Bilbao; Rosa Rademakers; Christian Haass; Ian R A Mackenzie
Journal:  Brain       Date:  2011-08-19       Impact factor: 13.501

7.  Yeast cells provide insight into alpha-synuclein biology and pathobiology.

Authors:  Tiago Fleming Outeiro; Susan Lindquist
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

Review 8.  Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models.

Authors:  Rubén Fernández-Santiago; Mario Ezquerra
Journal:  Stem Cells Int       Date:  2015-11-30       Impact factor: 5.443

9.  Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.

Authors:  Maria Armakola; Matthew J Higgins; Matthew D Figley; Sami J Barmada; Emily A Scarborough; Zamia Diaz; Xiaodong Fang; James Shorter; Nevan J Krogan; Steven Finkbeiner; Robert V Farese; Aaron D Gitler
Journal:  Nat Genet       Date:  2012-10-28       Impact factor: 38.330

10.  Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS.

Authors:  Ana Jovičić; Jerome Mertens; Steven Boeynaems; Elke Bogaert; Noori Chai; Shizuka B Yamada; Joseph W Paul; Shuying Sun; Joseph R Herdy; Gregor Bieri; Nicholas J Kramer; Fred H Gage; Ludo Van Den Bosch; Wim Robberecht; Aaron D Gitler
Journal:  Nat Neurosci       Date:  2015-09       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.